Johnson & Johnson Partners With Sail Biomedicines On In Vivo CAR-T Therapies, Secures $2.58B Acquisition Option; To Invest $785M In Sail, Expects The Agreements To Dilute Adjusted Operational Earnings Per Share And Adjusted Earnings Per Share By ~$0.18 In 2026 And ~$1.28 In 2027
Advances differentiated immunology program with the potential to address significant unmet need in immune-mediated diseaseNovel in vivo CAR-T platform is designed to generate CAR-T therapies directly within the body,
Johnson & Johnson is spending almost $3 billion to work with a smaller company on a new way to fight diseases by turning immune cells into healers inside your body. The company is betting this will help patients, but it will cost them money in the next couple years.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.